Kyverna Therapeutics Stock News

Kyverna Therapeutics is upgraded to 'Buy' based on strengthened financials and the potential for commercial launch by the end of 2026. Phase 2 data for mivocabtagene autoleucel shows strong efficacy and favorable safety in autoimmune indications, supporting late-stage advancement. A recent $100 million public offering and an untapped $125 million loan facility extend KYTX's cash runway into 202...

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript

EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offering price of $7.50 per share.

Kyverna Therapeutics (KYTX) is upgraded to "Strong Buy" following positive phase 2 data for miv-cel in SPS and MG indications. Company achieved a 46% average improvement in SPS patients in phase 2 KYSA-8 study, surpassing clinical benchmarks of 20% improvement, and plans a BLA filing for SPS in 1H 2026. Phase 3 portion enrollment of phase 2/3 KYSA-6 registrational study for miv-cel in Myastheni...

EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. Kyverna intends to grant the underwriters a 30-day o...

Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome, supporting a bullish outlook. KYTX's Miv-cel achieved significant clinical improvements and eliminated immunotherapy dependence, with a favorable safety profile and no high-grade CRS or ICANS events. A BLA submission for SPS is targeted for 1H26, with FDA approval prospects strengthened ...

Kyverna Therapeutics said on Monday its experimental cell therapy for treating patients with a rare movement disorder met the main goal of a mid-stage study, sending its shares surging 20% in premarket trading.

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026